Clinical Research
Filter News
Found 119,819 articles
-
The 2020 virtual meeting of the European Society of Medical Oncology is getting underway and companies are lining up to share information on their latest cancer treatments.
-
He also said they would be able to deliver 100 million doses to the U.S. government in the “first few months of 2021.”
-
BioSpace Global Roundup, Sept. 17
9/17/2020
Companies from across the globe provide updates on their businesses and pipelines. -
Cidara Therapeutics is hoping that its novel approach to influenza will prevent future “twindemic” double threats like the one we may face this year.
-
With both autumn and flu season fast approaching, nearly everyone is wondering whether we will endure another round of illnesses that will rival that of last spring.
-
3CL Protease Inhibitor NLC-001 Added to COVID-19-focused Joint Venture Between Todos Medical and NLC Pharma
9/17/2020
NLC-001 is a proprietary blend of plant extracts administered orally as dietary supplement US FDA granted Certificate of Free Sale for NLC-001 on August 28, 2020 JV evaluating potential of NLC-001 to treat COVID-19 in clinical studies in Israel Todos evaluating commercialization options for NLC-001 Worldwide
-
Expanding Their Existing Strategic Collaboration, GenScript ProBio Licensed Global Rights to Develop and Commercialize a SMAB Bispecific Antibody Molecule to REMD Biotherapeutics Inc.
9/17/2020
- On September 16 th , 2020, GenScript Pro B io and REMD Biotherapeutics Inc. (REMD) announced that REMD has licensed a bispecific antibody derived from the Single-domain antibody fused to Monoclonal Ab (SMAB) platform developed by GenScript Pro B io. REMD is a clinical-stage US biotechnology company committed to creating and
-
AlloVir Announces the FDA Clearance of Investigational New Drug Application (IND) for ALVR109 for the Treatment of High-Risk COVID-19 Patients
9/17/2020
- ALVR109 is an allogeneic, off-the-shelf virus-specific T cell therapy candidate designed to target SARS-CoV-2 for high-risk COVID-19 patients - Proof-of-concept clinical trial with ALVR109 to begin in Q42020 CAMBRIDGE, Mass., Sept. 17, 2020 (GLOBE NEWSWIRE) -- AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug application (IND) for ALVR109, an allogeneic, off-the-shelf vi
-
Artax Biopharma Announces Issuance of U.S. Composition of Matter Patent for Autoimmune Disease Program AX-158
9/17/2020
Artax Biopharma, Inc., a biotechnology company focused on transforming autoimmune disease treatment, announces today that the United States Patent and Trademark Office (USPTO) has granted a composition of matter patent for AX-158, the Company's lead a
-
Bio-Process Systems Alliance Releases 2020 Extractables/Leachables Guide
9/17/2020
The Bio-Process Systems Alliance (BPSA), the international association of the single-use bio-processing industry, is pleased to announce the release of its latest 2020 technical guide: Extractables/Lea
-
Diomics Announces Agreement With Department of Defense to Accelerate Development and Testing of Diocheck™ SARS-CoV-2 Immune Response Indicator Patch
9/17/2020
Diomics Announces Agreement With Department of Defense to Accelerate Development and Testing of Diocheck ™ SARS-CoV-2 Immune Response Indicator Patch Simple Skin Patch Empowers Individuals to Monitor for Immune Response to Help Stop COVID-19 Spread SAN DIEGO--( BUSINESS WIRE )-- Diomics, a San Diego-based biotech company, today announced that it has been awarded a $2,125,000 Medical Technology Enterprise Consortium (MTEC) Other Transaction Agree
-
Compelling New Research Links Increased Omega-3 Intake to Improved Cardiovascular Outcomes
9/17/2020
A new study, the most comprehensive analysis of the role of omega-3 dosage on cardiovascular prevention to date, provides compelling evidence for consuming more EPA and DHA (eicosapentaenoic acid and docosahexaenoic acid, respectively) omega-3 fats
-
MiMedx Concludes Enrollment for Phase 3 Plantar Fasciitis Trial
9/17/2020
Research in Plantar Fasciitis Advances Understanding of Amniotic Tissue as Potential Treatment for Chronic Musculoskeletal Pain and Function Disorders MARIETTA, Ga., Sept. 17, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced the conclusion of enrollment for a Phase 3 study of plantar fasciitis, an inflammation of the fibrous tissue along the botto
-
Dyadic Announces Collaboration with Jiangsu Hengrui Medicine for Biologic Drug Development
9/17/2020
Dyadic International, Inc. today announced collaboration with Jiangsu Hengrui Medicine Co., Ltd. ("Hengrui") (SSE:600276) to apply Dyadic's C1 technology to the development of selected Hengrui biologic drug(s).
-
Halozyme Announces Poster Presentation Of Data From Roche's Phase 1b Study Evaluating Atezolizumab For Subcutaneous Administration Utilizing Enhanze® In Non-Small Cell Lung Cancer
9/17/2020
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that its collaborator, Roche, presented a poster with data from Part 1 of its Phase 1b study (IMscin001) evaluating atezolizumab (Tecentriq ® ) for subcutaneous administration utilizing Halozyme's ENHANZE ® technology in patients with locally advanced or metastati
-
Raziel Announces China Market License Agreement with Fosun Pharma for RZL 012
9/17/2020
Raziel Therapeutics, a Pharmaceutical company developing next-generation novel prescription products for the medical aesthetics market announces licensing of its disruptive technology, RZL-012, to Fosun Pharma for milestone
-
Blueprint Medicines Presents Foundational Preclinical Data for BLU-945 Showing Robust Anti-Tumor Activity in Treatment-Resistant EGFR-Mutated Lung Cancer at ESMO Virtual Congress 2020
9/17/2020
-- BLU-945 demonstrates potent EGFR pathway inhibition against on-target resistance mutations -- -- BLU-945 shows exquisite wild-type EGFR and kinome selectivity, enabling potential for combination strategies -- -- Plan to initiate international Phase 1 dose-escalation trial of BLU-945 in patients with treatment-resistant EGFR-mutated NSCLC in 1H 2021 -- [17-September-2020]
-
Intensity Therapeutics Doses First Patient with Combination of INT230-6 and Bristol Myers Squibb’s Yervoy® in a Phase 2 Study
9/17/2020
Intensity Therapeutics, Inc. , a clinical-stage biotechnology company developing proprietary technology and products to kill tumors and increase immune system recognition of the cancer, today announced that the first patient has been dosed with a combination of INT230-6, the Company’s lead investigational product, and Yervoy® (ipilimumab), Bristol Myers Squibb’s (BMS) Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4)
-
Proniras Corporation Announces National Institute on Drug Abuse (NIDA) Grant Award to Pursue Treatment for Opioid Withdrawal
9/17/2020
Proniras Corporation, a biotechnology company committed to the development of life saving therapeutic products, today announced that the company and its collaborator, Indiana University (IU) School of Medicine, have received a $12.3 million grant from the National Institute on Drug Abuse (NIDA) to support development of the company’s proprietary molecule, tezampanel, as a treatment for opioid withdrawal syndrome. Tezampanel, a
-
Personalis Receives Contract Extension and New Task Order From the VA’s Million Veteran Program – Total Awarded to Date Now $175M
9/17/2020
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, announces that the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP) has exercised its option to extend our existing contract through September 2021. The VA also issued a new task order with an approximate value of up to $31M, and it has the right to issue additional task orders through the duration